UCB (OTCMKTS:UCBJY) Sets New 12-Month High – Should You Buy?

UCB SA (OTCMKTS:UCBJY) shares hit a new 52-week high during trading on Saturday . The stock traded as high as $165.71 and last traded at $165.10, with a volume of 30691 shares traded. The stock had previously closed at $161.8890.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Zacks Research cut shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Jefferies Financial Group raised UCB to a “moderate sell” rating in a research report on Sunday, October 26th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy”.

UCB Stock Up 2.0%

The business’s 50-day moving average price is $147.54 and its 200 day moving average price is $135.05. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.35 and a quick ratio of 1.01.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.